Aura Biosciences (AURA) Operating Leases (2021 - 2026)

Aura Biosciences has reported Operating Leases for 6 years, with the latest figure at $13.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 10.14% year-over-year to $13.7 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (down 10.14% YoY), and the FY2025 full-year result was $14.1 million, down 9.51% from the prior year.
• Operating Leases for Q1 2026 stood at $13.7 million, down from $14.1 million in the prior quarter.
• The five-year high for Operating Leases was $18.1 million in Q3 2022, with the low at $51000.0 in Q2 2022.
• Historically, Operating Leases has averaged $14.3 million across 5 years, with a median of $16.0 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Leases soared 34031.37% — and 2026, when it retreated 10.14%.
• Aura Biosciences' Operating Leases stood at $17.9 million in 2022, then retreated by 5.73% to $16.9 million in 2023, then dropped by 7.41% to $15.6 million in 2024, then slipped by 9.51% to $14.1 million in 2025, then slipped by 2.9% to $13.7 million in 2026.
• The last three Operating Leases figures came in at $13.7 million (Q1 2026), $14.1 million (Q4 2025), and $14.5 million (Q3 2025), per Business Quant data.